Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00962598 · ClinicalTrials.gov registry record · Phase 2
The Role Of Omega-3 Fatty Acids In Adolescent Depression
A Phase 2 study of Depressive Disorder, Major, sponsored by Icahn School of Medicine at Mount Sinai.
- Completed
- Registry status
- Phase 2
- Development phase
- 16
- Enrollment target
- 1
- Study location
NCT00962598 is a Phase 2 study of Depressive Disorder, Major that has completed, run by Icahn School of Medicine at Mount Sinai. The registered enrollment target is 16 participants, below the 242-participant average among 52 other Depressive Disorder, Major trials with a reported enrollment target (93% lower). The trial reports 1 study location across 1 state.
The verdict
NCT00962598, a Phase 2 study of Depressive Disorder, Major, has completed, sponsored by Icahn School of Medicine at Mount Sinai.
- COMPLETED
- Registry status
- Phase 2
- Development phase
- 16 participants
- Enrollment target
- 1
- Study location
Study Summary
The purpose of this study is to examine the effects of a 10-week Omega-3 Fatty Acid treatment phase on brain chemistry of adolescents with major depressive disorder (MDD) using proton magnetic resonance imaging.
Conditions Studied
Interventions
- DRUG Omega 3 Fatty Acids
- DIETARY_SUPPLEMENT Corn oil
Study Locations (1)
New York
- Icahn School of Medicine at Mount Sinai - New York
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 16 participants |
| Start Date | 2006-01 |
| Est. Completion | 2013-06 |
| Phase | Phase 2 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT00962598
The ClinicalTrials.gov registry entry for NCT00962598 describes a study currently listed as completed, categorized as Phase 2. The registered enrollment target is 16 participants, a figure that helps gauge the scale of data the investigators plan to collect, below the 242-participant average among 52 other Depressive Disorder, Major trials with a reported enrollment target (93% lower). The listed sponsor is Icahn School of Medicine at Mount Sinai, which has 708 total studies on file at ClinicalTrials.gov.
The record links to 1 condition, with Depressive Disorder, Major appearing as the primary indexed condition, and to 2 interventions - of which Omega 3 Fatty Acids is the first listed.
NCT00962598 reports 1 study location spanning 1 distinct geographic area - top geographies include New York.
Frequently Asked Questions
What is clinical trial NCT00962598 about?
NCT00962598 is a clinical study titled "The Role Of Omega-3 Fatty Acids In Adolescent Depression". The purpose of this study is to examine the effects of a 10-week Omega-3 Fatty Acid treatment phase on brain chemistry of adolescents with major depressive disorder (MDD) using proton magnetic resonance imaging.
What is the current status of trial NCT00962598?
This trial is currently completed. It is a Phase 2 study. The enrollment target is 16 participants. The study started on 2006-01. Estimated completion is 2013-06.
What conditions does trial NCT00962598 study?
This clinical trial studies the following conditions: Depressive Disorder, Major.
What interventions are being tested in trial NCT00962598?
The interventions under investigation include: Omega 3 Fatty Acids (DRUG), Corn oil (DIETARY_SUPPLEMENT).
Who is sponsoring clinical trial NCT00962598?
This trial is sponsored by Icahn School of Medicine at Mount Sinai, which has 708 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT00962598 being conducted?
This trial has 1 study location across New York. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Depressive Disorder, Major
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
-
Cognitive Dysfunction and Inflammation in Depression: Experimental Inhibition Via Infliximab
RECRUITING · Phase 2
-
Pharmaco-Neuroimaging Studies of Approach/Avoidance Behaviors and Post-Mortem Studies: Pharmacological Manipulation
RECRUITING · Phase 2
-
Investigation of the Antidepressant Effects of (2R,6R)-HNK, an Enhancer of Synaptic Glutamate Release, in Treatment-Resistant Depression
RECRUITING · Phase 2
-
A Study to Explore the Efficacy of JNJ-89495120 in the Treatment of Major Depressive Disorder
RECRUITING · Phase 2
-
Individualized Functional Connectivity Targeting in aiTBS for Depression
ACTIVE NOT RECRUITING · Phase 2
-
OnabotulinumtoxinA as Treatment for Major Depressive Disorder in Adult Females
COMPLETED · Phase 2
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.